Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial
,
(1)
,
(2)
,
,
,
(3)
,
(4)
,
(5)
,
(6)
,
(7)
,
(8)
,
(9)
,
(10)
,
(11)
,
(12)
,
(13)
,
,
(14)
,
(15)
,
,
(16)
,
(17)
,
(18)
,
(19)
,
(20)
,
(21)
,
(22)
,
(22)
,
(23)
,
(24)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Francoise Kraeber-Bodere
- Function : Author
Loïc Campion
- Function : Author
- PersonId : 982002
Anne Moreau
- Function : Author
- PersonId : 913458
Isabelle Soubeyran
- Function : Author
- PersonId : 762161
- ORCID : 0000-0001-7501-7622
Olivier Tournilhac
- Function : Author
- PersonId : 760569
- ORCID : 0000-0002-9438-621X
Henry Jardel
- Function : Author
- PersonId : 990450
Sophie Sadot
- Function : Author
Caroline Bodet-Milin
- Function : Author
- PersonId : 938697
Valérie Gouilleux-Gruart
- Function : Author
- PersonId : 180502
- IdHAL : valerie-gouilleux
- IdRef : 082604681
Pierre Soubeyran
- Function : Author
- PersonId : 752156
- IdHAL : plsoubhal2022
- ORCID : 0000-0003-3244-7299
- IdRef : 060718668
Abstract
Radioimmunotherapy represents a potential option as consolidation after chemoimmunotherapy in patients with diffuse large B-cell lymphoma who are not candidates for transplantation. We aimed to assess activity and toxicity of fractionated radioimmunotherapy using anti-CD22 90Y-epratuzumab tetraxetan as consolidation after front-line induction chemoimmunotherapy in untreated elderly patients with diffuse large B-cell lymphoma.